Breast cancers in monoallelic MUTYH germline mutation carriers have clinicopathological features overlapping with those in BRCA1 germline mutation carriers

被引:3
|
作者
Keske, Aysenur [1 ]
Weisman, Paul [1 ]
Ospina-Romero, Monica [1 ]
Raut, Prachi [1 ]
Smith-Simmer, Kelcy [2 ,3 ]
Zakas, Anna L. [2 ,3 ]
Flynn, Christopher [1 ]
Xu, Jin [1 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53706 USA
[2] Univ Wisconsin, Master Genet Counselor Studies, Acad Affairs, Sch Med & Publ Hlth, Madison, WI USA
[3] Univ Wisconsin, Oncol Genet, UW Hlth, Carbone Canc Ctr, Madison, WI USA
关键词
Hereditary breast cancer; MUTYH; Breast cancer with divergent grade/biomarker status; COLORECTAL-CANCER; RISK;
D O I
10.1007/s10549-023-07173-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Breast cancer patients referred to genetic counseling often undergo genetic testing with broad panels that include both breast cancer susceptibility genes as well as genes more specific for extramammary sites. As a result, patients are often incidentally found to have germline mutations in genes that are not necessarily related to breast cancer risk. One such gene is MUTYH. To understand the role MUTYH may play in breast cancer, the clinicopathological features of patients with monoallelic MUTYH germline mutation and breast cancer were examined.Methods The clinicopathological characteristics of the breast cancers from patients with monoallelic MUTYH mutation were compared to breast cancer patients with other germline mutations in known breast cancer susceptibility genes, including ATM, BRCA1/2, CHEK2, and PALB2. The breast cancer patients who received genetic counseling but tested negative for the aforementioned gene mutations were used as a control group.Results Histologic characteristics of the breast cancers arising in monoallelic MUTYH mutation carriers had significantly larger tumor size, higher tumor grade, and more high-risk biomarker profiles (i.e., Her2-positive and triple-negative) than breast cancer patients with susceptibility genes, except for BRCA1. MUTYH mutation carriers also showed a trend of more frequent intratumoral divergency in terms of tumor grade and biomarker profiles.Conclusion Although germline monoallelic MUTYH mutation is not thought to confer a meaningfully increased risk of breast cancer development, it may contribute to pathological aggressiveness and diversity of breast cancers when they sporadically arise in MUTYH carriers.
引用
收藏
页码:151 / 158
页数:8
相关论文
共 50 条
  • [1] Breast cancers in monoallelic MUTYH germline mutation carriers have clinicopathological features overlapping with those in BRCA1 germline mutation carriers
    Aysenur Keske
    Paul Weisman
    Monica Ospina-Romero
    Prachi Raut
    Kelcy Smith-Simmer
    Anna L. Zakas
    Christopher Flynn
    Jin Xu
    Breast Cancer Research and Treatment, 2024, 204 : 151 - 158
  • [2] Fertility Preservation in BRCA1/2 Germline Mutation Carriers: An Overview
    Silvestris, Erica
    Cormio, Gennaro
    Loizzi, Vera
    Corrado, Giacomo
    Arezzo, Francesca
    Petracca, Easter Anna
    LIFE-BASEL, 2024, 14 (05):
  • [3] Clinicopathologic Features of Preinvasive and Microinvasive Breast Lesions in BRCA Germline Mutation Carriers
    Sebastian, Christopher
    Wen, Yong Hannah
    Martinez, Julian
    Bowser, Zenica
    Akram, Muzaffar
    Norton, Larry
    Robson, Mark
    Reis-Filho, Jorge
    Brogi, Edi
    LABORATORY INVESTIGATION, 2015, 95 : 65A - 65A
  • [4] Clinicopathologic Features of Preinvasive and Microinvasive Breast Lesions in BRCA Germline Mutation Carriers
    Sebastiano, Christopher
    Wen, Yong Hannah
    Martinez, Julian
    Bowser, Zenica
    Akram, Muzaffar
    Norton, Larry
    Robson, Mark
    Reis-Filho, Jorge
    Brogi, Edi
    MODERN PATHOLOGY, 2015, 28 : 65A - 65A
  • [5] Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers
    Johannsson, O
    Loman, N
    Borg, Å
    Olsson, H
    LANCET, 1998, 352 (9137): : 1359 - 1360
  • [6] Pathologic findings at RRSO in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers
    Lee, YoungJae
    Kim, YongMan
    Lee, ShinWha
    CANCER RESEARCH, 2017, 77
  • [7] Mammographic density and breast cancer risk in germline BRCA1/2 mutation-carriers.
    Mitchell, G
    Warren, R
    Davies, R
    Brown, J
    Susan, P
    Warsi, I
    Easton, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 880S - 880S
  • [8] Germline and somatic mutation status in tissues from BRCA1/2 carriers
    Kotoula, Vassiliki
    Demiri, Efterpi
    Fostira, Florentia
    Vrettou, Eleni
    Papadopoulou, Kyriaki
    Tikas, Ioannis
    Papazisis, Konstantinos
    Zaramboukas, Thomas
    Asimaki-Vlachopoulou, Anthoula
    Miliaras, Spyros
    Fountzilas, Elena
    Ananiadis, Ananias
    Chrisafi, Sofia
    Poulios, Christos
    Natsiopoulos, Ioannis
    Tsiftsoglou, Aris
    Fountzilas, George
    CANCER RESEARCH, 2018, 78 (04)
  • [9] Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers
    van der Groep, P.
    van Diest, P. J.
    Menko, F. H.
    Bart, J.
    de Vries, E. G. E.
    van der Wall, E.
    JOURNAL OF CLINICAL PATHOLOGY, 2009, 62 (10) : 926 - 930
  • [10] BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma
    Blair, Alex B.
    Groot, Vincent P.
    Gemenetzis, Georgios
    Wei, Jishu
    Cameron, John L.
    Weiss, Matthew J.
    Goggins, Michael
    Wolfgang, Christopher L.
    Yu, Jun
    He, Jin
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2018, 226 (04) : 630 - 637